01:40 PM EDT, 10/08/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

After Pfizer Inc. (PFE 26 ****) and the U.S. government struck the first Most Favored Nation (MFN) drug pricing deal to lower drug prices in the U.S., we see policy risks related to tariffs to be less elevated for large U.S. biopharmaceuticals as we expect similar deals to be announced with other major players in the near term, which we think is lifting the investor sentiment for the broader sector. We see solid long-term growth prospects for the Health Care sector, which we think can benefit from long-term tailwinds such as continued innovation to discover and develop breakthrough therapies, an aging population, and rising life expectancy, which should drive strong demand for drugs and innovative treatments.